A recent study has identified a potential new tool to help detect gastrointestinal cancers — the platelet-to-high-density lipoprotein ratio, or PHR.
Researchers analyzed data from more than 19,000 adults in the National Health and Nutrition Examination Survey, spanning from 2010 to 2018. They found that individuals with the highest PHR levels were more than three times as likely to develop GI cancers — including stomach, colorectal and esophageal cancers — compared to those with the lowest levels, according to a July 30 Medical Dialogues report.
PHR reflects inflammation and lipid metabolism, both tied to cancer development. The association was strongest in older adults, men and people with obesity. The study also found that PHR may help improve early cancer detection, though further studies are needed.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
